Waldencast plc (WALD)
NASDAQ: WALD · IEX Real-Time Price · USD
5.30
-0.06 (-1.12%)
Apr 24, 2024, 4:00 PM EDT - Market closed

Company Description

Waldencast plc operates in the beauty and wellness business.

The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.

The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.

The company is headquartered in White Plains, New York.

Waldencast plc
Waldencast logo
Country United States
Founded 1988
IPO Date Mar 16, 2021
Industry Software - Application
Sector Technology
Employees 272
CEO Michel Brousset

Contact Details

Address:
10 Bank Street, Suite 560
White Plains, New York 10606
United States
Phone (917) 546-6828
Website waldencast.com

Stock Details

Ticker Symbol WALD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001840199
CUSIP Number G9503X103
ISIN Number JE00BPG99318
SIC Code 2844

Key Executives

Name Position
Felipe Dutra Executive Chairman
Michel Brousset Founder, Chief Executive Officer and Director
Hind Sebti Founder and Chief Growth Officer
Manuel Manfredi Chief Financial Officer
Elisabeth Milan General Counsel

Latest SEC Filings

Date Type Title
Mar 25, 2024 6-K Report of foreign issuer
Mar 21, 2024 6-K Report of foreign issuer
Mar 21, 2024 6-K Report of foreign issuer
Feb 26, 2024 6-K Report of foreign issuer
Feb 9, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 1, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 6-K Report of foreign issuer
Jan 31, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 16, 2024 6-K Report of foreign issuer
Jan 16, 2024 20-F Annual and transition report of foreign private issuers